News | 29 August 2011
Drug maker Valeant Pharmaceuticals (TSE:VRX) said Monday its board has approved a $300 million increase in its share buyback program. Mississauga-based Valeant plans to repurchase up to $1.8 billion in senior notes, convertible notes and common shares. ...
Click on the link to read the full article at Proactive Investors USA & Canada
(This link will open in a new window)